Cytospire Therapeutics has secured $83 million in Series A funding to progress its first-in-class pan-gamma delta T cell engagers into clinical trials for cancer. The approach aims to overcome safety ...
Belgian biotech UCB has made its second acquisition of the year, agreeing a front-loaded takeover of US biotech Candid ...
There are differences between familial and idiopathic pulmonary fibrosis in terms of cluster of differentiation 20 and CD3 expression.
KACTUS has published a technical framework for engineering 2+1 and trispecific T-cell engager therapeutics, addressing structural scaffold challenges for drug discovery teams advancing beyond ...
About Antengene Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for ...
Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”. BOSTON ...
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...
(MENAFN- GlobeNewsWire - Nasdaq) Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company's lead candidate, intranasal foralumab, for Long ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results